Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
690 participants
OBSERVATIONAL
2008-05-31
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Breast Cancer Detection: Comparison of Breast Tomosynthesis and Conventional Mammography
NCT01669148
Comparison Study of Breast Tomosynthesis Slice Thicknesses
NCT00957567
A Comparison of Recall Rates Between Conventional 2d Mammography and 2d Plus 3d (Tomosynthesis) Mammography in a Screening Population
NCT01569802
Digital 3D Breast Tomosynthesis Versus 2D in Clinical Evaluation of High Risk Women
NCT02209129
A Comparison of the 15 and 30 Acquisition Angle Breast Tomosynthesis Mammography for Breast Abnormalities
NCT00990483
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CROSSOVER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Breast cancer
Patients in treatment or post-treatment for breast cancer
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* female of any race and ethnicity
* 35 years or older
* after routine and diagnostic imaging, subject is categorized as a BI-RADS 3 and will undergo study imaging within 30 days of routine or diagnostic imaging.
* subject is returning for surveillance imaging after a categorization of a BI-RADS 3 and will undergo study imaging within 30 days of surveillance imaging GROUP 2
* female of any race and ethnicity
* 26 years or older
* subject has completed cancer treatment and is currently categorized as a BI-RADS 3 for surveillance imaging
* subject will undergo study imaging within 30 days of surveillance imaging GROUP 3
* female of any race and ethnicity
* 26 years or older
* subject is currently undergoing cancer treatment and is currently categorized as a BI-RADS 3 for surveillance imaging OR
* subject will undergo study imaging within 30 days of surveillance imaging
Exclusion Criteria
* subjects unable or unwilling to participate
* subjects who are unable or unwilling to tolerate compression
* subjects who are pregnant or who think they may be pregnant
* subjects who are breastfeeding
26 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hologic, Inc.
INDUSTRY
WellSpan Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Women's Imaging Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joanne Trapeni, DO
Role: PRINCIPAL_INVESTIGATOR
WellSpan Health
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0708023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.